 | Up a level |
Journal Article
Lueftner, D., Grischke, E. M., Fasching, P., Decker, T., Schneeweiss, A., Uleer, C., Foerster, F., Wimberger, P., Kluth-Pepper, B., Schubert, J., Bloch, W., Tesch, H., Schuetz, F. and Jackisch, C. (2015). Disease characteristics of subgroup patients treated with everolimus plus exemestane for < 12 months, >= 12 to < 18months, and >= 18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO. Eur. J. Cancer, 51. S. S288 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Wuerstlein, R., Kates, R., Gluz, O., Grischke, E. M., Schem, C., Thill, M., Hasmueller, S., Koehler, A., Otremba, B., Griesinger, F., Schindlbeck, C., Trojan, A., Otto, F., Knauer, M., Pusch, R. and Harbeck, N. (2019). Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study. Breast Cancer Res. Treat., 175 (2). S. 389 - 400. NEW YORK: SPRINGER. ISSN 1573-7217